Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass., feb. 1, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the compensation committee of karyopharm's board of directors granted stock options to purchase an aggregate of 124,500 shares of karyopharm's common stock to 15 newly-hired employees, with a grant date of january 31, 2022.
KPTI Ratings Summary
KPTI Quant Ranking